AstraZeneca (AZN) Stock Forecast & Price Target

£106.62 +50.00 (+0.47%)

As of 12:37 PM Eastern

AstraZeneca - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy

Based on 4 Analyst Ratings

Sell
0

Hold
1

Buy
3

Based on 4 Wall Street analysts who have issued ratings for AstraZeneca in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 4 analysts, 1 has given a hold rating, and 3 have given a buy rating for AZN.

Consensus Price Target

GBX 8,380

According to the 4 analysts' twelve-month price targets for AstraZeneca, the average price target is GBX 8,380. The highest price target for AZN is £140, while the lowest price target for AZN is GBX 140. The average price target represents a forecasted downside of -21.40% from the current price of £106.62.

Get the Latest News and Ratings for AZN and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for AstraZeneca and its competitors.

AZN Analyst Ratings Over Time

Type	Current Forecast 7/14/24 to 7/14/25	1 Month Ago 6/14/24 to 6/14/25	3 Months Ago 4/15/24 to 4/15/25	1 Year Ago 7/15/23 to 7/14/24
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	3 Buy rating(s)	3 Buy rating(s)	4 Buy rating(s)	6 Buy rating(s)
Hold	1 Hold rating(s)	2 Hold rating(s)	2 Hold rating(s)	2 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	1 Sell rating(s)
Consensus Price Target	GBX 8,380	GBX 6,303.50	GBX 6,303.50	£105.53
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Moderate Buy

AZN Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

AZN Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

AstraZeneca Stock vs. The Competition

Type	AstraZeneca	Medical Companies
Consensus Rating Score	2.75	2.80
Consensus Rating	Moderate Buy	Moderate Buy
News Sentiment Rating	Neutral News See Recent AZN News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Action	Rating	Price Target	Upside/Downside on Report Date
7/8/2025	Deutsche Bank Aktiengesellschaft 3 of 5 stars	Reiterated Rating	Hold	£110	+8.06%
5/16/2025	Berenberg Bank 2 of 5 stars	Reiterated Rating	Buy	GBX 140	-98.64%
4/29/2025	Shore Capital 1 of 5 stars	Reiterated Rating	Buy
2/19/2025	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight
7/2/2024	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Hold	GBX 71 ➝ GBX 74	-99.39%
5/28/2024	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy
4/8/2024	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight	£125	+18.56%
2/12/2024	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform
2/12/2024	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Sell	£107 ➝ GBX 9,900	+4.16%
9/25/2023	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target		£127 ➝ £129	+15.72%
Get the Latest News and Ratings for AZN and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for AstraZeneca and its competitors with MarketBeat's FREE daily newsletter.

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Monday at 01:30 PM ET.

Should I Buy AstraZeneca Stock? AZN Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Wednesday, July 9, 2025. Please send any questions or comments about these AstraZeneca pros and cons to contact@marketbeat.com.

AstraZeneca
Bull Case

Here are some ways that investors could benefit from investing in AstraZeneca PLC:

The current stock price is around $70, which may present a buying opportunity for investors looking for growth in the biopharmaceutical sector.
AstraZeneca PLC reported a strong earnings per share of $1.24, exceeding analysts' expectations, indicating robust financial performance and potential for future growth.
The company has shown a year-over-year revenue increase of 7.2%, suggesting a positive trend in sales and market demand for its products.
With a market capitalization of approximately $220 billion, AstraZeneca PLC is a significant player in the biopharmaceutical industry, providing stability and potential for long-term investment.
The firm has a solid return on equity of 33.14%, reflecting effective management and the ability to generate profits from shareholders' investments.

AstraZeneca
Bear Case

Investors should be bearish about investing in AstraZeneca PLC for these reasons:

The company has a relatively high P/E ratio of 28.57, which may indicate that the stock is overvalued compared to its earnings, potentially leading to lower returns.
AstraZeneca PLC's current ratio of 0.90 suggests that the company may have difficulty meeting its short-term liabilities, which could pose a risk to financial stability.
The firm has a beta of 0.37, indicating lower volatility compared to the market, which may limit potential gains during bullish market conditions.
Despite recent revenue growth, the company’s earnings per share decreased from $2.06 in the same quarter last year, raising concerns about profitability trends.
The debt-to-equity ratio of 0.65 indicates that the company is using a moderate amount of debt to finance its operations, which could be a risk if interest rates rise or if the company faces financial challenges.

AZN Forecast - Frequently Asked Questions

: According to the research reports of 4 Wall Street equities research analysts, the average twelve-month stock price forecast for AstraZeneca is GBX 8,380, with a high forecast of £140 and a low forecast of GBX 140.
: 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AstraZeneca in the last twelve months. There is currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" AZN shares.
: According to analysts, AstraZeneca's stock has a predicted downside of -21.40% based on their 12-month stock forecasts.
: AstraZeneca has been rated by research analysts at Berenberg Bank, Deutsche Bank Aktiengesellschaft, and Shore Capital in the past 90 days.
: Analysts like AstraZeneca less than other "medical" companies. The consensus rating score for AstraZeneca is 2.75 while the average consensus rating score for "medical" companies is 2.80. Learn more on how AZN compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top-Rated Stocks

More Ratings Tools

This page (LON:AZN) was last updated on 7/14/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

AstraZeneca (AZN) Stock Forecast & Price Target